文献速递呼吸道感染呼吸危重症与机械通气

静脉扎那米韦与口服奥司他韦治疗住院流感患者的国际随机双盲双模拟3期试验

Intravenous zanamivir or oral oseltamivir for hospitalised patients with influenza: an international, randomised, double-blind, double-dummy, phase 3 trial.
PubMed 文献 · Lancet Respir Med · 2017-01-14

这项国际随机双盲双模拟3期试验纳入626例≥16岁重症流感住院患者,比较静脉扎那米韦300mg、600mg与口服奥司他韦75mg每日两次治疗5-10天。主要终点为流感阳性人群的临床应答时间,结果显示600mg静脉扎那米韦未优于奥司他韦或300mg静脉扎那米韦,各组安全性相似。

要点

  • 600mg静脉扎那米韦的临床应答时间不优于口服奥司他韦或300mg静脉扎那米韦。
  • 奥司他韦组4例甲型H1N1pdm09患者出现H275Y耐药突变。

核心结论

  • 静脉扎那米韦600mg的临床应答时间不优于口服奥司他韦或静脉扎那米韦300mg。
  • 所有治疗方案在重症流感住院患者中安全性特征相似。

研究设计与样本

  • 国际、随机、双盲、双模拟、3期试验,纳入26个国家97家医院≥16岁重症流感住院患者。
  • 626例患者随机分配至静脉扎那米韦300mg(n=201)、600mg(n=209)或口服奥司他韦75mg(n=205),每日两次,治疗5-10天,随访28天。
  • 按症状出现≤4天或5-6天分层,主要终点为流感阳性人群的临床应答时间(生命体征稳定与出院复合终点)。

主要发现

  • 626例中488例(78%)为实验室确诊流感。
  • 奥司他韦组4例甲型H1N1pdm09患者出现H275Y耐药突变。
  • 治疗患者中373例(61%)报告不良事件,各组相似;最常见为腹泻、呼吸衰竭和便秘。

关键数值与推荐

  • 主要终点为流感阳性人群的临床应答时间,复合生命体征稳定和出院。
  • 给药方案为每日两次,疗程5-10天,随访28天。

临床怎么用

  • 重症流感住院患者中,静脉扎那米韦600mg未显示优于口服奥司他韦。
  • 口服奥司他韦仍是住院重症流感患者的合理治疗选择之一。
  • 需关注奥司他韦治疗中甲型H1N1pdm09的H275Y耐药突变。

局限性

  • 主要终点分析限于流感阳性人群(488/626)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Neuraminidase inhibitors are effective for the treatment of acute uncomplicated influenza. However, there is an unmet need for intravenous treatment for patients admitted to hospital with severe influenza. We studied whether intravenous zanamivir was a suitable treatment in this setting. METHODS: In this international, randomised, double-blind, double-dummy, phase 3 trial, we recruited patients aged 16 years or older with severe influenza admitted to 97 hospitals from 26 countries. We randomly assigned patients (1:1:1 stratified by symptom onset ≤4 days or 5-6 days) to receive 300 mg or 600 mg intravenous zanamivir, or standard-of-care (75 mg oral oseltamivir) twice a day for 5-10 days; patients were followed up for 28 days. The randomisation schedule, including stratification, was generated using GlaxoSmithKline's RandAll software. Patients, site study staff, and sponsor were masked to study treatment. The primary endpoint was time to clinical response-a composite of vital sign stabilisation and hospital discharge-in the influenza-positive population. The trial was powered to show an improvement of 1·5 days or greater with 600 mg intravenous zanamivir. Pharmacokinetic, safety, and virology endpoints were also assessed. This trial is registered with ClinicalTrials.gov, number NCT01231620. FINDINGS: Between Jan 15, 2011, and Feb 12, 2015, 626 patients were randomly assigned to receive 300 mg intravenous zanamivir (n=201), 600 mg intravenous zanamivir (n=209), or 75 mg oral oseltamivir (n=205) twice a day; 11 patients discontinued the study before receiving any study treatment. 488 (78%) of 626 patients had laboratory-confirmed influenza. Compared with a median time to clinical response of 5·14 days in the 600 mg intravenous zanamivir group, the median time to clinical response was 5·87 days (difference of -0·73 days, 95% CI -1·79 to 0·75; p=0·25) in the 300 mg intravenous zanamivir group and 5·63 days (difference of -0·48 days, 95% CI -2·11 to 0·97; p=0·39) in the oseltamivir group. Four patients with influenza A/H1N1pdm09 in the oseltamivir group developed H275Y resistance mutations. Adverse events were reported in 373 (61%) of treated patients and were similar across treatment groups; the most common adverse events (300 mg intravenous zanamivir, 600 mg intravenous zanamivir, oseltamivir) were diarrhoea (10 [5%], 15 [7%], 14 [7%]), respiratory failure (11 [5%], 14 [7%], 11 [5%]), and constipation (7 [3%], 13 [6%], 10 [5%]). 41 (7%) treated patients died during the study (15 [7%], 15 [7%], 11 [5%]); the most common causes of death were respiratory failure and septic shock. INTERPRETATION: Time to clinical response to intravenous zanamivir dosed at 600 mg was not superior to oseltamivir or 300 mg intravenous zanamivir. All treatments had a similar safety profile in hospitalised patients with severe influenza. FUNDING: GlaxoSmithKline.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. Marty FM, Vidal-Puigserver J, Clark C, et al. Intravenous zanamivir or oral oseltamivir for hospitalised patients with influenza: an international, randomised, double-blind, double-dummy, phase 3 trial. Lancet Respir Med. 2017. PMID: 28094141. doi:10.1016/S2213-2600(16)30435-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。